Chitosan oligosaccharide suppresses synovial inflammation via AMPK activation: An in vitro and in vivo study

Pharmacological Research

Volumn 113, Issue , 2016, Pages 458-467

  Kunanusornchai, Wanlop ^a   Witoonpanich, Bhee ^b   Pichyangkura, Rath ^c   Chatsudthipong, Varanuj ^a   Muanprasat, Chatchai ^a  

^a Mahidol University ^*  (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

AMPK; Chitosan oligosaccharide; NF B; Osteoarthritis; Synovial fibroblast

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; CHITOSAN OLIGOSACCHARIDE; CYCLOOXYGENASE 2; GLUCOSAMINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CHITOSAN; MITOGEN ACTIVATED PROTEIN KINASE; OLIGOSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOLOGY; NEW ZEALAND WHITE (RABBIT); NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYNOVIOCYTE; SYNOVITIS; SYNOVIUM; ANIMAL; CELL CULTURE; DRUG EFFECTS; EPITHELIUM CELL; INFLAMMATION; INTESTINE; LEPORIDAE; METABOLISM;

ANIMALS; ANTERIOR CRUCIATE LIGAMENT; CELLS, CULTURED; CHITOSAN; CYCLOOXYGENASE 2; EPITHELIAL CELLS; HUMANS; INFLAMMATION; INTESTINES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE SYNTHASE TYPE II; OLIGOSACCHARIDES; OSTEOARTHRITIS; RABBITS; SYNOVIOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84988711071     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.09.016     Document Type: Article

References (53)

1. [1] Hunter, D.J., Nevitt, M., Losina, E., Kraus, V., Biomarkers for osteoarthritis: current position and steps towards further validation. Best Pract. Res. Clin. Rheumatol. 28 (2014), 61–71.
2. [2] Roos, E.M., Arden, N.K., Strategies for the prevention of knee osteoarthritis. Nat. Rev. Rheumatol. 12 (2016), 92–101.
3. [3] Pelletier, J.P., Martel-Pelletier, J., Abramson, S.B., Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 44 (2001), 1237–1247.
4. [4] Robinson, W.H., Lepus, C.M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T.M., Sokolove, J., Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 12:10 (2016), 580–592.
5. [5] Abramson, S.B., Attur, M., Amin, A.R., Clancy, R., Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr. Rheumatol. Rep. 3 (2001), 535–541.
6. [6] Smith, M.D., Triantafillou, S., Parker, A., Youssef, P.P., Coleman, M., Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J. Rheumatol. 24 (1997), 365–371.
7. [7] Attur, M.G., Patel, I.R., Patel, R.N., Abramson, S.B., Amin, A.R., Autocrine production of il-1 beta by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, il-6, prostaglandin e2, and il-8. Proc. Assoc. Am. Phys. 110 (1998), 65–72.
8. [8] Loeser, R.F., Goldring, S.R., Scanzello, C.R., Goldring, M.B., Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 64 (2012), 1697–1707.
9. [9] Goldring, M.B., Otero, M., Inflammation in osteoarthritis. Curr. Opin. Rheumatol. 23 (2011), 471–478.
10. [10] Bijlsma, J.W., Berenbaum, F., Lafeber, F.P., Osteoarthritis: an update with relevance for clinical practice. Lancet 377 (2011), 2115–2126.
11. [11] Hardie, D.G., Ampk: positive and negative regulation, and its role in whole-body energy homeostasis. Curr. Opin. Cell Biol. 33C (2014), 1–7.
12. [12] Koh, S.J., Kim, J.M., Kim, I.K., Ko, S.H., Kim, J.S., Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer. J. Gastroenterol. Hepatol. 29 (2014), 502–510.
13. [13] Huang, N.L., Chiang, S.H., Hsueh, C.H., Liang, Y.J., Chen, Y.J., Lai, L.P., Metformin inhibits tnf-alpha-induced ikappab kinase phosphorylation, ikappab-alpha degradation and il-6 production in endothelial cells through pi3k-dependent ampk phosphorylation. Int. J. Cardiol. 134 (2009), 169–175.
14. [14] Katerelos, M., Mudge, S.J., Stapleton, D., Auwardt, R.B., Fraser, S.A., Chen, C.G., Kemp, B.E., Power, D.A., 5-Aminoimidazole-4-carboxamide ribonucleoside and amp-activated protein kinase inhibit signalling through nf-kappab. Immunol. Cell Biol. 88 (2010), 754–760.
15. [15] Hawley, S.A., Fullerton, M.D., Ross, F.A., Schertzer, J.D., Chevtzoff, C., Walker, K.J., Peggie, M.W., Zibrova, D., Green, K.A., Mustard, K.J., Kemp, B.E., Sakamoto, K., Steinberg, G.R., Hardie, D.G., The ancient drug salicylate directly activates amp-activated protein kinase. Science 336 (2012), 918–922.
16. [16] Chi, Y., Li, K., Yan, Q., Koizumi, S., Shi, L., Takahashi, S., Zhu, Y., Matsue, H., Takeda, M., Kitamura, M., Yao, J., Nonsteroidal anti-inflammatory drug flufenamic acid is a potent activator of amp-activated protein kinase. J. Pharmacol. Exp. Ther. 339 (2011), 257–266.
17. [17] Grahame Hardie, D., Amp-activated protein kinase: a key regulator of energy balance with many roles in human disease. J. Intern. Med. 276 (2014), 543–559.
18. [18] Je, J.Y., Kim, S.K., Chitooligosaccharides as potential nutraceuticals: production and bioactivities. Adv. Food Nutr. Res. 65 (2012), 321–336.
19. [19] Chae, S.Y., Jang, M.K., Nah, J.W., Influence of molecular weight on oral absorption of water soluble chitosans. J. Control. Release 102 (2005), 383–394.
20. [20] Azuma, K., Osaki, T., Minami, S., Okamoto, Y., Anticancer and anti-inflammatory properties of chitin and chitosan oligosaccharides. J. Funct. Biomater. 6 (2015), 33–49.
21. [21] Yousef, M., Pichyangkura, R., Soodvilai, S., Chatsudthipong, V., Muanprasat, C., Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action. Pharmacol. Res. 66 (2012), 66–79.
22. [22] Muanprasat, C., Wongkrasant, P., Satitsri, S., Moonwiriyakit, A., Pongkorpsakol, P., Mattaveewong, T., Pichyangkura, R., Chatsudthipong, V., Activation of ampk by chitosan oligosaccharide in intestinal epithelial cells: mechanism of action and potential applications in intestinal disorders. Biochem. Pharmacol. 96 (2015), 225–236.
23. [23] Jeong, H.W., Cho, S.Y., Kim, S., Shin, E.S., Kim, J.M., Song, M.J., Park, P.J., Sohn, J.H., Park, H., Seo, D.B., Kim, W.G., Lee, S.J., Chitooligosaccharide induces mitochondrial biogenesis and increases exercise endurance through the activation of sirt1 and ampk in rats. PLoS One, 7, 2012, e40073.
24. [24] Momberger, T.S., Levick, J.R., Mason, R.M., Hyaluronan secretion by synoviocytes is mechanosensitive. Matrix Biol. 24 (2005), 510–519.
25. [25] Denizot, F., Lang, R., Rapid colorimetric assay for cell growth and survival. J. Immunol. Methods 89 (1986), 271–277.
26. [26] Khan, H., Kusakabe, K.T., Wakitani, S., Hiyama, M., Takeshita, A., Kiso, Y., Expression and localization of no synthase isoenzymes (inos and enos) in development of the rabbit placenta. J. Reprod. Dev. 58 (2012), 231–236.
27. [27] Swanson, E.R., Ohno, T., Abdollahian, D., Rousseau, B., Effects of raised-intensity phonation on inflammatory mediator gene expression in normal rabbit vocal fold. Otolaryngol. Head Neck Surg. 143 (2010), 567–572.
28. [28] Smith, M., Cake, M., Ghosh, P., Schiavinato, A., Read, R., Little, C., Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intra-articular hyaluronan therapy. Rheumatology 47 (2008), 1172–1178.
29. [29] Yoshioka, M., Coutts, R.D., Amiel, D., Hacker, S.A., Characterization of a model of osteoarthritis in the rabbit knee. Osteoarthr. Cartil. 4 (1996), 87–98.
30. [30] Tiraloche, G., Girard, C., Chouinard, L., Sampalis, J., Moquin, L., Ionescu, M., Reiner, A., Poole, A.R., Laverty, S., Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum. 52 (2005), 1118–1128.
31. [31] Lisignoli, G., Grassi, F., Piacentini, A., Cocchini, B., Remiddi, G., Bevilacqua, C., Facchini, A., Hyaluronan does not affect cytokine and chemokine expression in osteoarthritic chondrocytes and synoviocytes. Osteoarthr. Cartil. 9 (2001), 161–168.
32. [32] Hough, A.J., Sokoloff, L., Pathology of osteoarthritis. Arthritis Allied Cond. 13 (1989), 1945–1968.
33. [33] Yousef, M., Pichyangkura, R., Soodvilai, S., Chatsudthipong, V., Muanprasat, C., Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action. Pharmacol. Res. 66 (2012), 66–79.
34. [34] Kong, C.-S., Kim, J.-A., Kim, S.-K., Anti-obesity effect of sulfated glucosamine by ampk signal pathway in 3t3-l1 adipocytes. Food Chem. Toxicol. 47 (2009), 2401–2406.
35. [35] Plagemann, P.G., Erbe, J., Transport and metabolism of glucosamine by cultured novikoff rat hepatoma cells and effects on nucleotide pools. Cancer Res. 33 (1973), 482–492.
36. [36] Uitterlinden, E., Koevoet, J., Verkoelen, C., Bierma-Zeinstra, S., Jahr, H., Weinans, H., Verhaar, J., Van Osch, G., Glucosamine increases hyaluronic acid production in human osteoarthritic synovium explants. BMC Musculoskelet. Disord., 9, 2008, 1.
37. [37] Xiong, W.Y., Yi, Y., Liu, H.Z., Wang, H., Liu, J.H., Ying, G.Q., Selective carboxypropionylation of chitosan: synthesis, characterization, blood compatibility, and degradation. Carbohydr. Res. 346 (2011), 1217–1223.
38. [38] Chiu, C.-Y., Chan, I.-L., Yang, T.-H., Liu, S.-H., Chiang, M.-T., Supplementation of chitosan alleviates high-fat diet-enhanced lipogenesis in rats via adenosine monophosphate (amp)-activated protein kinase activation and inhibition of lipogenesis-associated genes. J. Agric. Food Chem. 63 (2015), 2979–2988.
39. [39] Shao, K., Han, B., Dong, W., Song, F., Liu, W., Liu, W., Pharmacokinetics and biodegradation performance of a hydroxypropyl chitosan derivative. J. Ocean Univ. China 14 (2015), 888–896.
40. [40] Li, H., Jiang, Z., Han, B., Niu, S., Dong, W., Liu, W., Pharmacokinetics and biodegradation of chitosan in rats. J. Ocean Univ. China 14 (2015), 897–904.
41. [41] Li, Y., Xu, Q., Wei, P., Cheng, L., Peng, Q., Li, S., Yin, H., Du, Y., Chitosan oligosaccharides downregulate the expression of e-selectin and icam-1 induced by lps in endothelial cells by inhibiting map kinase signaling. Int. J. Mol. Med. 33 (2014), 392–400.
42. [42] Liu, H.T., Li, W.M., Li, X.Y., Xu, Q.S., Liu, Q.S., Bai, X.F., Yu, C., Du, Y.G., Chitosan oligosaccharides inhibit the expression of interleukin-6 in lipopolysaccharide-induced human umbilical vein endothelial cells through p38 and erk1/2 protein kinases. Basic Clin. Pharmacol. Toxicol. 106 (2010), 362–371.
43. [43] Salminen, A., Hyttinen, J.M., Kaarniranta, K., Amp-activated protein kinase inhibits nf-kappab signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. (Berl.) 89 (2011), 667–676.
44. [44] Yan, H., Zhou, H.-f., Hu, Y., Pham, C.T., Suppression of experimental arthritis through amp-activated protein kinase activation and autophagy modulation. J. Rheum. Dis. Treat., 1, 2015, 5.
45. [45] Amin, A.R., Regulation of tumor necrosis factor-alpha and tumor necrosis factor converting enzyme in human osteoarthritis. Osteoarthr. Cartil. 7 (1999), 392–394.
46. [46] Larsson, S., Englund, M., Struglics, A., Lohmander, L.S., Interleukin-6 and tumor necrosis factor alpha in synovial fluid are associated with progression of radiographic knee osteoarthritis in subjects with previous meniscectomy. Osteoarthr. Cartil. 23 (2015), 1906–1914.
47. [47] Kou, S., Wu, Y., Meta-analysis of tumor necrosis factor alpha -308 polymorphism and knee osteoarthritis risk. BMC Musculoskelet. Disord., 15, 2014, 373.
48. [48] van de Loo, F.A., Joosten, L.A., van Lent, P.L., Arntz, O.J., van den Berg, W.B., Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum. 38 (1995), 164–172.
49. [49] Vignon, E., Bejui, J., Mathieu, P., Hartmann, J., Ville, G., Evreux, J., Descotes, J., Histological cartilage changes in a rabbit model of osteoarthritis. J. Rheumatol. 14 (1987), 104–106.
50. [50] Hongbin, W., Jingyuan, D., Linyun, C., Yuming, D., Carboxymethylated chitin reduces mmp-1 expression in rabbit aclt osteoarthritic cartilage. Ann. Rheum. Dis. 63 (2004), 369–372.
51. [51] Liu, S.-Q., Qiu, B., Chen, H., Peng, L.-y., Du, Y.-M., The effects of carboxymethylated chitosan on metalloproteinase-1, -3 and tissue inhibitor of metalloproteinase-1 gene expression in cartilage of experimental osteoarthritis. Rheumatol. Int. 26 (2005), 52–57.
52. [52] Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited. FASEB J. 22 (2008), 659–661.
53. [53] Mhurchu, C.N., Poppitt, S.D., McGill, A.T., Leahy, F.E., Bennett, D.A., Lin, R.B., Ormrod, D., Ward, L., Strik, C., Rodgers, A., The effect of the dietary supplement, chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int. J. Obes. Relat. Metab. Disord.: J. Int. Assoc. Stud. Obes. 28 (2004), 1149–1156.